Microvast Holdings announces departure of chief financial officer
Medicus Pharma Ltd. (NASDAQ:MDCX) announced Tuesday that it has engaged Deloitte LLP as its exclusive lead financial adviser to seek potential partners for an out-licensing transaction involving its Doxorubicin Microneedle Array (D-MNA) for the treatment of Basal Cell Carcinoma in adults. The engagement was formalized through an agreement entered into on July 29.
According to a statement released by the company, Deloitte will assist Medicus Pharma in identifying one or more partners for a transaction, which may take the form of a license, option, or other agreed structure. Under the terms of the engagement, Medicus Pharma will pay Deloitte a retainer fee and a contingent success fee if a transaction is completed.
Medicus Pharma’s common shares and warrants are listed on the NASDAQ Capital Market under the symbols MDCX and MDCXW, respectively.
This information is based on a press release statement included in a filing with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.